We suggest that the anti-cancer effect of MET combined with either antifolate agent occurs through the inhibition of cancer cell progression, increase expression of p53 and Bax, decrease expression of Bcl-2, rise in the number of total apoptotic cells, inhibition of migration ability, decrease in ATP production, inhibition of the glycolysis pathway and induction of mitochondrial damage. The gene discussed is BCL2; the disease is cancer.